Peroxisome proliferator-activated receptors: Nuclear control of metabolism

Endocrine Reviews

Volumn 20, Issue 5, 1999, Pages 649-688

  Desvergne, B ^a   Wahli, W ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 BROMOPALMITIC ACID; ACYL COENZYME A DEHYDROGENASE; DNA; ENZYME INHIBITOR; FATTY ACID; FENOPROFEN; FLUFENAMIC ACID; IBUPROFEN; INDOMETACIN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ROSIGLITAZONE; TOMELUKAST; TROGLITAZONE;

ATHEROSCLEROSIS; CELL NUCLEUS; CHROMOSOMAL LOCALIZATION; DNA BINDING; FATTY ACID METABOLISM; GENE FUNCTION; GENE TARGETING; GENETIC ORGANIZATION; HUMAN; INFLAMMATION; LIGAND BINDING; LIPID ANALYSIS; LIPID METABOLISM; MEMBRANE PERMEABILITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; TRANSACTIVATION;

EID: 0033305213     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.20.5.649     Document Type: Review

References (408)

1. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
2. A unified nomenclature system for the nuclear receptor superfamily
3. The LXRs: A new class of oxysterol receptors
4. Rat PPARδ contains a CGG triplet repeat and is prominently expressed in the thalamic nuclei
5. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
6. Identification of two mPPAR related receptors and evidence for the existence of five subfamily members
7. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver
8. Differential expression and activation of family murine peroxisome proliferator-activated receptors
9. Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors
10. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor
11. cDNA cloning and characterization of the transcriptional activities of the hamster peroxisome proliferator-activated receptor haPPARγ
12. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids
13. cDNA cloning, chromosomal mapping and functional characterization of the human peroxisome proliferator activated receptor
14. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: Expression in hematopoietic cells and chromosomal mapping
15. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors
16. Evolution of the nuclear receptor gene superfamily
17. The early evolution of eukaryotes - A geological perspective
18. Origins of genes - Big bang or continuous creation
19. Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-γ (hPPARγ) gene
20. Assignment of the human nuclear hormone receptor, NUC1 (PPARδ), to chromosome 6p21.1-p21.2
21. Chromosomal localisation, inducibility, tissue-specific expression and strain differences in three murine peroxisome proliferator-activated receptor genes
22. Structure of the mouse peroxisome proliferator activated receptor α gene
23. Xenopus peroxisome proliferator activated receptors: Genomic organization, response element recognition, heterodimer formation with retinoid X receptor and activation by fatty acids
24. Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene: Alternative promoter use and different splicing yield two mPPARγ isoforms
25. The organization, promoter analysis, and expression of the human PPAR-γ gene
26. PPARgamma3 mRNA: A distinct PPARγ mRNA subtype transcribed from an independent promoter
27. Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers
28. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors
29. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene
30. Novel sequence determinants in peroxisome proliferator signaling
31. Polarity and specific sequence requirements of PPAR-RXR heterodimer binding to DNA: A functional analysis of the malic enzyme gene PPRE
32. DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements: Importance of the 5' flanking region
33. Identification of an extended half-site motif required for the function of peroxisome proliferator-activated receptor alpha
34. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors
35. The RXR heterodimers and orphan receptors
36. A carboxyl-terminal extension of the zinc finger domain contributes to the specificity and polarity of peroxisome proliferator-activated receptor DNA binding
37. Determinants for selective RAR and TR recognition of direct repeat HREs
38. Differential orientations of the DNA-binding domain and carboxy-terminal dimerization interface regulate binding site selection by nuclear receptor heterodimers
39. The patterns of binding of RAR, RXR and TR homodimers and heterodimers to direct repeats are dictated by the binding specificities of the DNA binding domains
40. Structure of the retinoid X receptor α DNA binding domain: A helix required for homodimeric DNA binding
41. DNA target selectivity by the vitamin-D3 receptor: Mechanism of dimer binding to an asymmetric repeat element
42. Ordered binding of retinoic acid and retinoid x receptors to asymmetric response elements involves determinants adjacent to the DNA-binding domain
43. The dimerization interfaces formed between the DNA binding domains of RXR, RAR and TR determine the binding specificity and polarity of the full-length receptors to direct repeats
44. Dimerization interfaces formed between the DNA binding domains determine the cooperative binding of RXR/RAR and RXR/TR heterodimers to DR5 and DR4 elements
45. Structural determinants of nuclear receptor assembly on DNA direct repeats
46. Structural elements of an orphan nuclear receptor-DNA complex
47. Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element
48. The directly repeated RG(G/T)TCA motifs of the rat and mouse cellular retinol-binding protein II genes are promiscuous binding sites for RAR, RXR, HNF-4 and ARP-1 homo- and heterodimers
49. DNA binding and transcription activation specificity of hepatocyte nuclear factor 4
50. Antagonism of COUP-TF and PPARα/RXRα on the activation of the malic enzyme gene promoter - Modulation by 9-cis RA
51. Chicken ovalbumin upstream promoter transcription factor (COUP - TF) binds to a peroxisome proliferator-responsive element and antagonizes peroxisome proliferator-mediated signalling
52. Transactivation of the peroxisome proliferator-activated receptor is differentially modulated by hepatocyte nuclear factor-4
53. Transcriptional suppression of the transferrin gene by hypolipidemic peroxisome proliferators
54. Multiple parameters determine the specificity of transcriptional response by nuclear receptors HNF-4, ARP-1, PPAR, RAR, RXR through common response elements
55. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements
56. Retinoid x receptor and peroxisome proliferator-activated receptor activate an estrogen responsive gene independent of the estrogen receptor
57. Thyroid hormone (T3) inhibits ciprofibrate-induced transcription of gene encoding β-oxidation enzymes: Cross-talk between peroxisome proliferator and T3 signaling pathways
58. Peroxisome proliferator-activated receptor mediates cross-talk with thyroid hormone receptor by competition for retinoid X receptor: Possible role of a leucine zipper-like heptad repeat
59. The human peroxisome proliferator-activated receptor (PPAR) subtype NUC1 represses the activation of hPPARα and thyroid hormone receptors
60. Activation of the prolactin gene by peroxisome-proliferator activated receptor-α appears to be DNA binding-independent
61. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid x receptor heterodimers
62. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
63. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation
64. 15-Deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
65. The PPARα-leukotriene B4 pathway to inflammation control
66. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ
67. PPARα structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents
68. Adopting orphans: Finding ligands
69. Scintillation proximity assay
70. Development of a scintillation proximity assay for peroxisome proliferator-activated receptor gamma ligand binding domain
71. Ligand-induced peroxisome proliferator-activated receptor α conformational change
72. Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for PPARα and PPARδ
73. Fatty acids, eicosanoids and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by CARLA
74. Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects
75. Peroxisome proliferator-activated receptor (PPAR) agonists
76. Structural requirements and cell-type specificity for ligand activation of peroxisome proliferator-activated receptors
77. Phytanic acid activates the peroxisome proliferator-activated receptor α (PPARα) in sterol carrier protein2-/sterol carrier protein x-deficient mice
78. Leukotriene B4: Agonist for the fat regulator PPARα
79. Chemical probes that differentially modulate PPARα and BLTR, nuclear and cell surface receptors for leukotriene B4
80. Translocation and leukotriene synthetic capacity of nuclear 5-lipoxygenase in rat basophilic leukemia cells and alveolar macrophages
81. Determinants of 5-lipoxygenase nuclear localisation using green fluorescent protein/5-lipoxygenase fusion proteins
82. cis-Parinaric acid is a ligand for the human peroxisome proliferator activated receptor γ: Development of a novel spectrophotometric assay for the discovery of PPARγ ligands
83. Ligand selectivity of the peroxisome proliferator-activated receptor α
84. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: Binding and activation correlate with antidiabetic actions in db/db mice
85. N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents
86. Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library
87. Crystal structure of the ligand-binding domain of the human nuclear receptor RXRα
88. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid
89. A structural role for hormone in the thyroid hormone receptor
90. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors
91. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ
92. Crystal structure of the ligand binding domain of the human nuclear receptor PPARγ
93. A single amino acid change in the mouse peroxisome proliferator-activated receptor alpha alters transcriptional responses to peroxisome proliferators
94. The peroxisome proliferator-activated receptor α is a phosphoprotein: Regulation by insulin
95. Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor α by phosphorylation of a ligand-independent trans-activating domain
96. Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor γ
97. Regulation of peroxisome proliferator-activated receptor γ activity by mitogen-activated protein kinase
98. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ
99. c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-γ1 and negatively regulates its transcriptional activity
100. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor γ
101. Interdomain communication regulating ligand binding by PPAR-γ
102. Insulin regulation of phosphoenolpyruvate carboxykinase gene expression does not require activation of the Ras/mitogen-activated protein kinase signaling pathway
103. Cross-talk between Janus kinase-signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor-α (PPARα) signaling pathways
104. Interaction of the peroxisome-proliferator-activated receptor and retinoid X-receptor
105. Retinoids increase human apolipoprotein A-II expression through activation of the retinoid X receptor but not the retinoic acid receptor
106. 9-cis-Retinoic acid enhances fatty acid-induced expression of the liver fatty acid-binding protein gene
107. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists
108. RXR agonists activate PPARα-inducible genes, lower triglycerides, and raise HDL levels in vivo
109. Identification and characterization of a stereospecific human enzyme that catalyzes 9-cis-retinol oxidation. A possible role in 9-cis-retinoic acid formation
110. The identification of a 9-cis retinol dehydrogenase in the mouse embryo reveals a pathway for synthesis of 9-cis retinoic acid
111. Unique response pathways are established by allosteric interactions among nuclear hormone receptors
112. A novel pathway for vitamin A signaling mediated by RXR heterodimerization with NGFI-B and NURR1
113. LXR, a nuclear receptor that defines a distinct retinoid response pathway
114. Retinoid X receptor α forms tetramers in solution
115. Heterodimer formation by retinoid X receptor: Regulation by ligands and by the receptor's self-association properties
116. A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR
117. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice
118. Retinoids increase human Apo-CIII expression at the transcriptional level via the retinoid X receptor
119. Identification of the first retinoid X receptor homodimer antagonist
120. Activation of specific RXR heterodimers by an antagonist of RXR homodimers
121. A decade of molecular biology of retinoic acid receptors
122. Retinoid x receptor (RXR) within the RXR-retinoic acid receptor heterodimer binds its ligand and enhances retinoid-dependent gene expression
123. A mutation mimicking ligand-induced conformational change yields a constitutive RXR that senses allosteric effects in heterodimers
124. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor γ (PPARγ)
125. Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site
126. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation
127. Nuclear receptor coactivators
128. Nuclear receptor coactivators and corepressors
129. Stoichiometric and steric principles governing repression by nuclear hormone receptors
130. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
131. Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor γ
132. A signature motif in transcriptional co-activators mediates binding to nuclear receptor
133. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation
134. Nuclear receptors have distinct affinities for coactivators: Characterization by fluorescence resonance energy transfer
135. Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators
136. Mouse steroid receptor coactivator-1 is not essential for peroxisome proliferator-activated receptor α-regulated gene expression
137. p300 Functions as a coactivator for the peroxisome proliferator-activated receptor alpha
138. The antidiabetic agent thiazolidinedione stimulates the interaction between PPAR γ and CBP
139. Transactivation by retinoid x receptor-peroxisome proliferator-activated receptor γ (PPARγ) heterodimers: Intermolecular synergy requires only the PPARγ hormone-dependent activation function
140. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors
141. p300 Is a component of an estrogen receptor coactivator complex
142. Role of CBP/P300 in nuclear receptor signalling
143. Activation of cAMP and mitogen responsive genes relies on a common nuclear factor
144. Nuclear protein CBP is a coactivator for the transcription factor CREB
145. Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation
146. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-α
147. Two contact regions between Stat1 and CBP/p300 in interferon γ signaling
148. Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300
149. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator
150. Conjunction dysfunction: CBP/p300 in human disease
151. Transcription- A growing coactivator network
152. The p300/CBP family: Integrating signals with transcription factors and chromatin
153. The phantom ligand effect: Allosteric control of transcription by the retinoid X receptor
154. The RXRα ligand-dependent activation function (AF-2) is important for mouse development
155. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis
156. Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor
157. The TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion
158. A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system
159. Receptor-interacting protein 140 interacts with and inhibits transactivation by, peroxisome proliferator-activated receptor α and liver-X-receptor α
160. A regulatory role for RIP140 in nuclear receptor activation
161. Functional interactions of peroxisome proliferator-activated receptor, retinoid-X receptor, and Sp1 in the transcriptional regulation of the acyl-coenzyme-A oxidase promoter
162. The CBP co-activator is a histone acetyltransferase
163. The transcriptional coactivators p300 and CBP are histone acetyltransferases
164. The acetyltransferase activity of CBP stimulates transcription
165. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor α,β, and γ and the retinoid X receptor α, β, and γ in rat central nervous system
166. Differential expression of peroxisome proliferator-activated receptor-α, -β, and -γ during rat embryonic development
167. Differential expression of peroxisome proliferator-activated receptors: Tissue distribution of PPAR-α, -β and -γ in the adult rat
168. PPAR tissue distribution and interactions with other hormone-signaling pathways
169. Peroxisome proliferator activated receptor-α expression in human liver
170. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists
171. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: No alteration in adipose tissue of obese and NIDDM patients
172. Dexamethasone and insulin demonstrate marked and opposite regulation of the steady-state mRNA level of the peroxisomal proliferator-activated receptor (PPAR) in hepatic cells - Hormonal modulation of fatty-acid-induced transcription
173. Regulation of the peroxisome proliferator-activated receptor α gene by glucocorticoids
174. Expression of the peroxisome proliferator-activated receptor α gene is stimulated by stress and follows a diurnal rhythm
175. Peroxisome proliferator-activated receptors: A nuclear receptor signaling pathway in lipid physiology
176. Suppressive effect of growth hormone on the expression of peroxisome proliferator-activated receptor in cultured rat hepatocytes
177. Expression of the peroxisome proliferator-activated receptor gene is decreased in experimental alcoholic liver disease
178. Regulation of peroxisome proliferator-activated receptor α mRNA in rat liver
179. Role of peroxisome proliferator-activated receptor α in disease of pancreatic β cells
180. Positive regulation of the peroxisomal β-oxydation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR)
181. Member of the peroxisome proliferator-activated receptor family of transcription factors is differentially expressed by oligodendrocytes
182. Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARδ
183. mPPARγ2: Tissue-specific regulator of an adipocyte enhancer
184. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa
185. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APC(Min)/+ mice
186. Activators of the nuclear receptor PPARγ enhance colon polyp formation
187. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids
188. TNFα-mediated inhibition and reversal of adipocyte differentiation is accompanied by suppressed expression of PPARγ without effects on Pref-1 expression
189. Decreased expression of murine PPARγ in adipose tissue during endotoxemia
190. Developmental and nutritional changes of ob and PPARγ2 gene expression in rat white adipose tissue
191. The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPARγ and aP2 in adipose tissue of high-fat-fed rats
192. Subcutaneous or visceral adipose tissue expression of the PPARgamma gene is not altered in the fatty (fa/fa) Zucker rat
193. Regulation of PPARγ gene expression by nutrition and obesity in rodents
194. Relationships of PPARγ and PPARγ2 mRNA levels to obesity, diabetes and hyperinsulinaemia in rhesus monkeys
195. Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor-γ in human adipocytes
196. Skeletal muscle peroxisome proliferator-activated receptor γ expression in obesity and non-insulin-dependent diabetes mellitus
197. Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPARγ) gene in diabetic Caucasians: Identification of a Pro12Ala PPAR γ2 missense mutation
198. A Pro12Ala substitution in PPARγ 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
199. Pro12Ala missense mutation of the peroxisome proliferator-activated receptor γ and diabetes mellitus
200. Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor gamma 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men
201. Human peroxisome proliferator-activated receptor-gamma2: Genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes
202. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations
203. A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2
204. Genome wide search for genes influencing percent body fat in Pima Indians: Suggestive linkage at chromosome 11q21-q22
205. Transcriptional regulation of cellular retinol-binding protein, type II gene expression in small intestine by dietary fat
206. Fatty acid regulation of fatty acid-binding protein expression in the small intestine
207. Evidence for transcriptional induction of the liver fatty-acid-binding-protein gene by bezafibrate in the small intestine
208. Regulation of the biosynthesis of two distinct fatty acid-binding proteins in rat liver and intestine. Influences of sex difference and of clofibrate
209. Localization and regulation of the putative membrane fatty-acid transporter (FAT) in the small intestine. Comparison with fatty acid-binding proteins (FABP)
210. Scavenger receptor BI: A cell surface receptor for high density lipoprotein
211. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease
212. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice
213. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates
214. Repression by ARP-1 sensitizes apolipoprotein-AI gene responsiveness to RXRα and retinoic acid
215. Transcriptional regulation of human apolipoprotein genes ApoB, ApoCIII, and ApoAII by members of the steroid hormone receptor superfamily HNF-4, ARP-1, EAR-2, and EAR-3
216. Factors participating in the liver-specific expression of the human apolipoprotein A-II gene and their significance for transcription
217. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression
218. Orphan nuclear receptor HNF-4 binds to the human coagulation factor VII promoter
219. Tissue-specific expression of the gene encoding hepatocyte nuclear factor-1 may involve hepatocyte nuclear factor-4
220. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators
221. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner
222. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter
223. Biochemical mechanisms of induction of hepatic peroxisome proliferation
224. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators
225. Diverse peroxisome proliferator-activated receptors bind to the peroxisome proliferator-responsive elements of the rat hydratase/dehydrogenase and fatty acyl-CoA oxidase genes but differentially induce expression
226. Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase
227. Metabolic role of mammalian peroxisomes
228. Reevaluation of the pathways for the biosynthesis of polyunsaturated fatty acids
229. Fatty acid cycling in human hepatoma cells and the effects of troglitazone
230. Co-ordinate induction of hepatic mitochondrial and peroxisomal carnitine acyltransferase synthesis by diet and drugs
231. Changes in hepatic lipid metabolism associated with lipid accumulation and its reversal in rats given the peroxisome proliferator LY171883
232. Co-regulation of tissue-specific alternative human carnitine palmitoyltransferase Iβ gene promoters by fatty acid enzyme substrate
233. Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor
234. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor α
235. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression
236. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids
237. A mitochondrial ketogenic enzyme regulates its gene expression by association with the nuclear receptor PPARα
238. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα)
239. Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting
240. A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: The PPARα-null mouse as a model of fatty acid oxidation disorders
241. PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene
242. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor α-deficient mice
243. Peroxisome proliferator-activated receptor α-isoform deficiency leads to progressive dyslipidemia with sexually dismorphic obesity and steatosis
244. Estrogen-induced production of a peroxisome proliferator-activated receptor (PPAR) ligand in a PPARγ-expressing tissue
245. The peroxisome proliferator activated receptor regulates malic enzyme gene expression
246. Coordinate suppression of liver acetyl-CoA carboxylase and fatty acid synthetase by polyunsaturated fat
247. Polyunsaturated fatty acids regulate lipogenic and peroxisomal gene expression by independent mechanisms
248. Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression
249. Effect of beta-naphthoflavone on mitochondrial supply of reducing equivalents for monooxygenation in periportal and pericentral regions of the liver lobule
250. Polyunsaturated fatty acid suppression of hepatic fatty acid synthase and S14 gene expression does not require peroxisome proliferator-activated receptor α
251. Fatty acyl-CoA thioesters are ligands of hepatic nuclear factor-4-α
252. Peroxisomal leukotriene degradation: Biochemical and clinical implications
253. The peroxisome proliferator-activated receptor mediates the induction of CYP4A6, a cytochrome-P450 fatty-acid ω-hydroxylase, by clofibric acid
254. Identification and characterization of DNA elements implicated in the regulation of CYP4A1 transcription
255. Peroxisome proliferator-activated receptor α controls the hepatic CYP4A induction adaptive response to starvation and diabetes
256. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
257. Adipocyte fatty acid-binding protein: Regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent
258. Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells
259. Peroxisome proliferator-activated receptor (PPAR) gamma: Adipose-predominant expression and induction early in adipocyte differentiation
260. Perinatal expression of genes that may participate in lipid metabolism by lipid-laden lung fibroblasts
261. Regulating adipogenesis
262. Conditional ectopic expression of C/EBPβ in NIH-3T3 cells induces PPARγ and stimulates adipogenesis
263. CAAT/enhancer binding proteins directly modulate transcription from the peroxisome proliferator-activated receptor γ2 promoter
264. Reconstitution of insulin-sensitive glucose transport in fibroblasts requires expression of both PPARγ and C/EBPα
265. Human translocation liposarcoma-CCAAT/enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBPβ function
266. Impaired energy homeostasis in C/EBPα knockout mice
267. Defective adipocyte differentiation in mice lacking the C/EBPβ and/or C/EBPδ gene
268. Life without white fat: A transgenic mouse
269. Induction of peroxisome proliferator-activated receptor γ during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPβ, C/EBPδ, and glucocorticoids
270. ADD1: A novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation
271. Add1/SREBP1 activates PPARγ through the production of endogenous ligand
272. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: Model for congenital generalized lipodystrophy
273. Regulation of peroxisome proliferator-activated receptor γ expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: Implications for adipocyte differentiation and metabolism
274. Differential activation of adipogenesis by multiple PPAR isoforms
275. Expression of peroxisome proliferator-activated receptor PPARδ promtes induction of PPARγ and adipocyte differentiation in 3T3C2 fibroblasts
276. Differentiation of embryonic stem cells into adipocytes in vitro
277. Transdifferentiation of myoblasts by the adipogenic transcription factors PPARγ and C/EBPα
278. Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells
279. Trans-differentiation of myoblasts to adipoblasts: Triggering effects of fatty acids and thiazolidinediones
280. Peroxisome proliferator-activated receptor γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells
281. Pathogenesis of thiazolidinedione induced hematoxicity in the dog
282. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene
283. Identification of a functional peroxisome proliferator-activated responsive element in the murine fatty acid transport protein gene
284. Adipose expression of the phosphoenolpyruvate carboxykinase promoter requires peroxisome proliferator-activated receptor gamma and 9-cis-retinoic acid receptor binding to an adipocyte-specific enhancer in vivo
285. PPARγ, induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPα during the conversion of 3T3 fibroblasts into adipocytes
286. Thiazolidinediones and insulin resistance: Peroxisome proliferator activated receptor γ activation stimulates expression of the CAP gene
287. A novel, multifunctional c-Cbl binding protein in insulin receptor signaling in 3T3-L1 adipocytes
288. PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes
289. Development of obesity in transgenic mice after genetic ablation of brown adipose tissue
290. Uncoupling protein-3 expression in rodent skeletal muscle is modulated by food intake but not by changes in environmental temperature
291. Uncoupling protein-2: A novel gene linked to obesity and hyperinsulinemia
292. Uncoupling protein-3: A new member of the mitochondrial carrier family with tissue-specific expression
293. Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, β3-adrenergic agonists, and leptin
294. Role of UCP homologues in skeletal muscles and brown adipose tissue: Mediators of thermogenesis or regulators of lipids as fuel substrate?
295. Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese
296. Activation of the nuclear receptor peroxisome proliferator-activated γ promotes brown adipocyte differentiation
297. Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: Regulation by peroxisome proliferator-activated receptor γ
298. Peroxisome proliferator-activated receptors γ and α mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression
299. Activators of peroxisome proliferator-activated receptor-α induce the expression of the uncoupling protein-3 gene in skeletal muscle: A potential mechanism for the lipid intake-dependent activation of uncoupling protein-3 gene expression at birth
300. Abnormal nonshivering thermogenesis in mice with inherited defects of fatty acid oxidation
301. Adipogenesis and obesity: Rounding out the big picture
302. Journey from cachexia to obesity by TNF
303. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-α
304. Tumor necrosis factor α inhibits signaling from the insulin receptor
305. IRS1-mediated inhibition of insulin receptor tyrosine kinase activity in TNFα- and obesity-induced insulin resistance
306. Tumor necrosis factor-α causes insulin receptor substrate-2-mediated insulin resistance and inhibits insulin-induced adipogenesis in fetal brown adipocytes
307. Protection from obesity-induced insulin resistance in mice lacking TNF-α function
308. Obesity and diabetes in TNF-α receptor-deficient mice
309. Adipose tissue-derived tumor necrosis factor activity correlates with fat cell size but not insulin action in aging rats
310. Negative regulation of peroxisome proliferator-activated receptor-γ gene expression contributes to the antiadipogenic effects of tumor necrosis factor-α
311. The short- and long-term effects of tumor necrosis factor-α and BRL 49653 on peroxisome proliferator-activated receptor (PPAR)γ2 gene expression and other adipocyte genes
312. BRL 49653 blocks the lipolytic actions of tumor necrosis factor-α: A potential new insulin-sensitizing mechanism for thiazolidinediones
313. Pioglitazone time-dependently reduces tumour necrosis factor-α level in muscle and improves metabolic abnormalities in Wistar fatty rats
314. Thiazolidinediones block tumor necrosis factor α-induced inhibition of insulin signaling
315. Positional cloning of the mouse obese gene and its human homologue
316. Adipocyte differentiation and leptin expression
317. Leptin and the regulation of body weight in mammals
318. Leptin levels reflect body lipid content in mice: Evidence for diet-induced resistance to leptin action
319. Serum immunoreactive-leptin concentrations in normal-weight and obese humans
320. A nutrient-sensing pathway regulates leptin gene expression in muscle and fat
321. Signals that regulate food intake and energy homeostasis
322. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ
323. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes
324. Down-regulation of the expression of the Obese gene by an antidiabetic thiazolidinelione in Zucker diabetic fatty rats and db/db mice
325. Functional antagonism between CCAAT/enhancer binding protein α and peroxisome proliferator-activated receptor γ on the leptin promoter
326. Targeted expression of a toxin gene to adipose tissue: Transgenic mice resistant to obesity
327. Troglitazone action is independent of adipose tissue
328. Fatty acid-induced beta cell apoptosis: A link between obesity and diabetes
329. Troglitazone lowers islet fat and restores β cell function of Zucker diabetic fatty rats
330. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-γ
331. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARγ agonist) action
332. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis
333. Dietary n-3 fatty acids accelerate catabolism of leukotriene B4 in human granulocytes
334. Induction of peroxisomal enzymes and a 64-kDa peptide in cultured mouse macrophages treated with clofibrate
335. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
336. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging
337. The peroxisome proliferator-activated receptor γ is a negative regulator of macrophage activation
338. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
339. Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells
340. Cyclopentone prostaglandins suppress activation of microglia: Down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2
341. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs
342. The pathogenesis of atherosclerosis: A perspective for the 1990s
343. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL
344. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
345. Macrophages in human atheroma contain PPARγ: Differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPArγ activation in mononuclear phagocytes in vitro
346. Oxidized low density lipoprotein inhibits lipopolysaccharide-induced binding of nuclear factor-κB to DNA and the subsequent expression of tumor necrosis factor-α and interleukin-1β in macrophages
347. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ
348. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells
349. Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells
350. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-[Delta]12,14-prostaglandin J2
351. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARγ in endothelial function
352. PPAR-gamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease
353. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages
354. Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes
355. Correlation between expression of peroxisome proliferator-activated receptor β and squamous differentiation in epidermal and tracheobronchial epithelial cells
356. Inhibition of skin development by targeted expression of a dominant-negative retinoic acid receptor
357. Targeting expression of a dominant-negative retinoic acid receptor mutant in the epidermis of transgenic mice results in loss of barrier function
358. Activators of the nuclear hormone receptors PPARα and FXR accelerate the development of the fetal epidermal permeability barrier
359. Keratinocyte differentiation is stimulated by activators of the nuclear hormone receptor PPARα
360. Ligands and activators of nuclear hormone receptors regulate epidermal differentiation during fetal rat skin development
361. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?
362. Induction of replicative DNA synthesis and PPAR α-dependent gene transcription by Wy-14 643 in primary rat hepatocyte and non-parenchymal cell co-cultures
363. Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin
364. Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor α (PPAR α)
365. Role of peroxisome proliferator-activated receptor α in altered cell cycle regulation in mouse liver
366. Peroxisome proliferator-activated receptor α: Role in rodent liver cancer and species differences
367. Fenofibrate and human liver. Lack of proliferation of peroxisomes
368. Peroxisome proliferator-activated receptor-α and the pleiotropic responses to peroxisome proliferators
369. The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: Significance for species differences in response to PPs
370. Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators
371. Peroxisome proliferator activated receptor γ, CCAAT/enhancer-binding protein α, and cell cycle status regulate the commitment to adipocyte differentiation
372. Activation of peroxisome proliferator-activated receptor γ bypasses the function of the retinoblastoma protein in adipocyte differentiation
373. PPARγ induces cell cycle withdrawal: Inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A
374. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor g and the retinoid X receptor
375. Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18 (INK4c) and p21 (Waf1/Cip1), during adipogenesis
376. Terminal differentiation of human breast cancer through PPARγ
377. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
378. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
379. Activation of PPAR-gamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells
380. Differentiation and reversal of malignant changes in colon cancer through PPARγ
381. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo
382. PPARγ and colorectal carcinoma: Conflicts in a nuclear family
383. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors
384. Molecular cloning and properties of a full-length putative thyroid hormone receptor coactivator
385. The interaction of the vitamin D receptor with nuclear receptor corepressors and coactivators
386. p300 And estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation
387. CREB-binding protein in androgen receptor-mediated signaling
388. p300 Interacts with the N- and C-terminal part of PPARγ2 in a ligand-independent and -dependent manner, respectively
389. An adipogenic cofactor bound by the differentiation domain of PPARγ
390. Cloning and characterization of mouse RIP140, a corepressor for nuclear orphan receptor TR2
391. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells
392. Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor γ
393. SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers
394. A transcriptional co-repressor that interacts with nuclear hormone receptors
395. Gene silencing by chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) is mediated by transcriptional corepressors, nuclear receptor-corepressor (N-CoR) and silencing mediator for retinoic acid receptor and thyroid hormone receptor (SMRT)
396. Polarity-specific activities of retinoic acid receptors determined by a co-repressor
397. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor
398. A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains
399. Identification of nuclear corepressor as peroxisome proliferator-activated receptor α interacting protein
400. Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of rat acyl-CoA oxidase gene
401. Additions and corrections to identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene
402. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element
403. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor
404. Mode of action of peroxisome proliferators as hypolipidemic drugs
405. PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene
406. A role for fatty acid and liver fatty acid binding protein in peroxisome proliferation?
407. Genomic organization and promoter sequence of a gene encoding a rat liver-specific type-I transport protein